Clinical Data Psyched For Vilazodone NDA Filing In Second Half
This article was originally published in The Pink Sheet Daily
Executive Summary
Company anticipates data from a second Phase III trial evaluating the SSRI/5HT1A partial agonist for depression in the second quarter.
You may also be interested in...
Clinical Data submits antidepressant with companion Dx
Clinical Data submits its NDA for vilazodone, a dual-acting selective serotonin reuptake inhibitor and a 5-HT1A receptor partial agonist, for the treatment of major depressive disorder. In two eight-week Phase III trials, vilazodone was superior to placebo, with statistical significance for the primary and multiple secondary endpoints. Vilazodone would be set apart on the market by the availability of a companion diagnostic to identify patients most likely to benefit from treatment. Clinical Data is co-developing the test along with the drug. It estimates that peak sales could surpass $2 billion with the companion diagnostic (1"The Pink Sheet" DAILY, April 8, 2009)
Clinical Data submits antidepressant with companion Dx
Clinical Data submits its NDA for vilazodone, a dual-acting selective serotonin reuptake inhibitor and a 5-HT1A receptor partial agonist, for the treatment of major depressive disorder. In two eight-week Phase III trials, vilazodone was superior to placebo, with statistical significance for the primary and multiple secondary endpoints. Vilazodone would be set apart on the market by the availability of a companion diagnostic to identify patients most likely to benefit from treatment. Clinical Data is co-developing the test along with the drug. It estimates that peak sales could surpass $2 billion with the companion diagnostic (1"The Pink Sheet" DAILY, April 8, 2009)
“Not Approvable” Letter Leaves Vanda’s Schizophrenia Drug With Cloudy Future
FDA requests additional Phase III comparative study and safety data for iloperidone.